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Background: Recurrent aphthous ulcers (RAU) are common painful inflammatory lesions of the mucous lining of 
the mouth. Endocan, previously identified as endothelial cell specific molecule-1, is implicated as a vital player in 
the regulation of several inflammatory processes. A number of inflammatory cytokines and pro-angiogenic growth 
factors including VEGF upregulate endothelial cells synthesis and expression of endocan.
Material and Methods: Clinical scores of pain and ulcer size as well as level of endocan and VEGF were determined 
in swaps from aphthous ulcer and contra lateral normal mucosa in 30 patients (nine males and twenty one females) 
with age ranging from 18 to 45 years and mean age is 31.5 years.
Results: In the early days of ulcer development, ulcer showed statistically significantly higher mean endocan (8.2 
±5.3) and VEGF levels (1220.7 ±294.6) than control healthy mucosal site (1.1 ±0.5) and (518.6 ± 61.7) respecti-
vely. An increase in endocan is associated with an increase in pain score and vice versa. A statistically significant 
positive correlation were also found between endocan and VEGF levels.
Conclusions: Endocan and VEGF are strongly associated with the destructive phase of minor aphthous ulcers es-
pecially Endocan which was positively correlated with pain severity.




Recurrent aphthous ulcers (RAU) is the most communal 
inflammatory ulcer affecting the oral mucosa (1) with 
the prevalence of 5 - 25 % in the overall population. The 
peak period of RAU occurs in the second decade and 
the first occurrence being in early childhood or even in 
later (2). The decreased occurrence of RAU in elderly 
may be due to age-dependent variations in the acquired 
and innate immune systems, designated as immunose-
nescence (3).
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Based on the clinical presentation, three forms of RAU 
can be designated: minor, major or herpetiform aphthous 
ulcers. The minor type is the most common affecting 
about 80% of patients (1). It occurs as round or oval ul-
cers <1 mm in diameter affecting non-keratinized mu-
cosa as the buccal and labial mucosa and floor of mouth 
with the floor covered by a grayish white pseudomem-
brane and is surrounded by a halo of erythema. The ul-
cers usually heal in 10–14 days with no scarring (4).
Thus far, the etiopathogenesis of this disease remains 
uncertain and seems to be multifactorial. The possible 
risk factors that could trigger the condition include: food 
allergies, vitamin deficiencies, genetic predisposition, 
bacterial and viral infections, systemic ailments (e.g., ul-
cerative colitis, Crohn’s disease, celiac disease, AIDS), 
hormonal disorders, amplified oxidative stress, mecha-
nical irritation and stress (5-7).
The most accepted theory regarding the aetiology of RAU 
is that these predisposing factors or unknown antigenic 
stimulation triggers oral mucosal keratinocytes to trans-
form into a target of the uncontrolled action of lympho-
cytes, neutrophils and monocytes resulting in liberation 
of acute inflammatory mediators, damage of oral mucosal 
cells, thus the appearance of an aphthous ulcer (8,9).
The acute inflammatory mediators liberated during the 
initiation of the ulcerative process that included cyto-
kines for instance TNF-α, IFN-ϒ, IL-2 and IL-2, along 
with the migration of other lymphocytes, langerhans 
cells and neutrophils also causes an over expression of 
Vascular Cell Adhesion Molecules (VCAM), Intercellu-
lar Adhesion Molecules (ICAM-1) and Selectine E lea-
ding to more lymphocytic accumulation and invasion of 
the epithelium locally (10).
Vascular endothelial growth factor (VEGF) is a powerful 
endothelium-specific cytokine that effectively stimula-
tes angiogenesis, inflammation, endothelium-dependent 
vasodilatation and amplified microvascular permeability 
(11). It is principally produced by vascular endothelial 
cells, macrophages and neutrophils. In inflammatory re-
actions its production is stimulated, and VEGF itself en-
dorses the inflammatory processes. An increase in VEGF 
levels have been described in several inflammatory and 
autoimmune diseases (12,13). In their study, Arbiser et 
al. (14) reported elevation in VEGF levels in addition to 
its receptors in RAU and advocated that oral aphthous 
ulcerations might be highly angiogenic.
Endocan is a unique human endothelial cell- specific 
molecule (ESM). It was initially cloned from a human 
endothelial cell DNA library by Lassalle et al. (15). En-
docan is secreted by epithelial cells of the renal distal 
tubules, vascular endothelial cells, bronchi and lung sub 
mucosal glands (16). A number of cytokines and growth 
factors regulate the expression of endocan by vascular 
endothelium. Binding of endocan to human leukocytes 
occurs via the integrin leukocyte function-associated an-
tigen (LFA)-1 and hinders the interactions of LFA- 1/
intercellular adhesion molecule (ICAM)-1 and, possibly, 
LFA-1-mediated leukocyte functions (17). Endocan ex-
pression has been reported to be intensely up-regulated 
via proangiogenic molecules as VEGF-A and VEGF-C 
which are known to be critical mediators of lymphan-
giogenesis, angiogenesis, and cancer progression (18). 
To the best of our knowledge, there is no previous study 
investigating the association of endocan and VEGF 
in recurrent aphthous ulcers. Therefore, in the present 
study, we aimed to investigate the expression levels of 
Endocan and VEGF in minor aphthous ulcer lesions du-
ring both the active and the healing stages.
Material and Methods
This study was conducted in Faculty of Dentistry, Cairo 
University after approval of the faculty Research Ethics 
Committee.
Thirty subjects (nine males and twenty one females) 
were recruited from outpatient clinic of Oral Medicine, 
and Periodontology Department, Faculty of Dentistry, 
Cairo University.
Inclusion criteria included patients having minor aph-
thous ulcers with no other specific pathology affecting 
the oral mucosa. The patients were systemically free 
according to Cornell medical index. The appearance of 
the ulcers should not be more than 3 days at the time of 
enrolment in this study.
Exclusion criteria included: patient with any systemic 
disease producing oral ulcerations as Bechets disease, 
ulcerative colitis, Reiter syndrome, haematological di-
seases, Cohns disease, allergic conditions, nutritional 
deficiencies, in addition to patients who have received 
any medical treatment in the past six months, pregnant 
or lactating mothers and smokers.
During the period of clinical study, the subjects had not 
to use any topical agents such as mouth wash and topical 
medication for treating aphthous ulcer and avoid taking 
spicy foods, sour drinks and coffee. Patients were infor-
med of the nature and objectives of the study and they 
were educated about importance to come for the follow 
up visits till the end of the study. After that the enrolled 
patients signed a written informed consent.
Clinical evaluation of the patients:
1. Recording of pain score:
Assessment of pain was done via Visual Analogue Sca-
le (VAS) that is comprised of a 10 cm line enclosing 
equidistant subdivisions of the following concomitant 
scores: randling.
Score 0 = no pain
Score 1 = pain with rough aggravation
Score 2 = pain with moderate aggravation
Score 3 = pain with slight aggravation
Score 4 = constant pain
Score 5 = severe pain
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Patients were informed that aggravation referred to 
anything that may move or touch the ulcer area and also 
that pain associated with gentle touching of the lesion 
was greater than that of rough handling.
Pain scores were assessed 2 times; in the second and the 
tenth day of the ulceration period. Pain scores were plot-
ted in a table and compared in the study site statistically.
2. Assessment of ulcer size  as follows:
Under good lightening conditions, the ulcer area was 
dried carefully then a transparent plastic sheet was cut to 
facilitate its application directly on the ulcer. Then using 
a permanent water proof marker pen, the circumference 
of the ulcer was traced on the plastic sheet. The tracing 
was then placed on graph paper and the size of the ul-
cer was calculated in mms. Ulcer sizes were assessed 2 
times; in the second and the tenth day of the ulceration 
period. The sizes of the lesions were plotted in a table 
and compared in the study site statistically.
Exfoliative cytology and preparation of smears:
Swabs were taken from the ulcer at the second and tenth 
days of the ulceration period as well as from the contra-
lateral healthy mucosa to assess the level of Endocan 
and VEGF.
The sampling procedure was done as described pre-
viously by Spafford et al. (19). Aphthous ulcers were 
cleaned slowly with a cotton wetted by saline and then 
the ulcers were swabbed with a sterile cotton roll. This 
technique was applied by a stroke of the mucosa 3 to 5 
times to collect the cell exfoliations.  In addition, swabs 
from the contralateral clinically unaffected mucosa were 
obtained from all subjects as well to compare the level of 
Endocan and VEGF in the ulcer and the healthy mucosa.
After swabbing of the ulcer and mucosa by the cotton 
roll, the sample was allowed to dissolve in an eppendorff 
tube containing Phosphate Buffered Saline (PBS) solu-
tion. Samples were then stored at – 70O C until being 
used for laboratory analysis.
Assessment of Endocan and VEGF:
Endocan Assay:
Endocan was measured using ELISA kit supplied by 
EIAab, China Catalogue No: E2112h. This kit allows 
for the in vitro quantitative determination of human En-
docan concentrations in serum, tissue homogenates and 
different biological fluids. The microtiter plate of the kit 
has been pre-coated with an endocan specific antibody. 
This is followed by addition of samples and standards 
to the microtiter plate wells with a biotin-conjugated 
polyclonal endocan specific antibody. Horseradish Pe-
roxidase (HRP) is then added to and incubated in the 
microplate well. Then substrate solution (TMB) is added 
to all wells. The reaction is finished by the addition of a 
stop solution of sulphuric acid and the color intensity is 
measured by spectrophotometer at a wavelength of 450 
nm ± 2 nm. The Endocan concentration in the samples is 
specified from the standard curve.
VEGF Assay:
The concentration of VEGF was determined by a quan-
titative sandwich enzyme immunoassay kit (R&D Sys-
tems, Minneapolis, MN.) according to manufacturer’s 
directions. Briefly, 100 ml assay diluent RD1W was 
added to each well. After dilution of samples, 100 ml 
sample was added per well. It was covered with the ad-
hesive strip provided and incubated for 2 hours at room 
temperature. Aspiration and washing for each well was 
done and repeated twice for a total of three washes. A 
total of 200 ml VEGF conjugate was added to each well, 
covered with a new adhesive strip, and incubated at 
room temperature for 2 hours. Aspiration and washing 
was repeated. A total of 200 ml substrate solution was 
added to each well, protected from light, and incubated 
at room temperature for 25 minutes. Then, 50 ml stop 
solution was added to each well. The plate was gently 
tapped to confirm complete mixing. Assessment of op-
tical density of the wells was done within 30 minutes 
via a microplate reader set to 450 nm. VEGF levels in 
samples were appraised via the standard curve plotted 
utilizing the optical density values with the standards. 
Samples and standards were assayed in duplicate as re-
commended by the manufacturer.
-Statistical Analysis
Data were presented as mean, standard deviation (SD), me-
dian and range values. Data were explored for normality 
by checking the data distribution, calculating the mean and 
median values and using Kolmogorov-Smirnov and Shapi-
ro-Wilk tests. All data showed non-parametric distribution. 
The study is a split-mouth design; so Wilcoxon signed-rank 
test was used to study the changes after treatment as well as 
to compare between ulcer and control sides.
Spearman’s correlation coefficient was used to determi-
ne significant correlation between different variables. 
The significance level was set at P ≤ 0.05. Statistical 
analysis was performed with IBM® SPSS® Statistics 
Version 20 for Windows.
Results
The present study included a total of thirty subjects (nine 
males and twenty one females). The mean ± standard 
deviation (SD) values of age were 33.2 ± 10.2 years with 
a minimum of 18 years and a maximum of 45 years old.
Comparison of the different variables between the se-
cond day and the tenth day
Pain score and ulcer size:
The pain and ulcer size were recorded at the second day 
and again at the tenth day of ulcer period. Pain score 
decreased significantly from 3.6 ± (0.9) at the second 
day to 1.0 ± (0.7) at the tenth day with p-value <0.001*.
The same was observed with the ulcer size which was 
35.1 ± (9.8) mm2 at the second day and significantly re-
duced to 11.6 ± (5.8) mm2 at the tenth day with p-value 
<0.001* (Table 1).
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Endocan and VEGF level:
At the second day of ulcer activity, the ulcer swabs 
showed statistically significantly higher mean endocan 
levels 8.2 ± (5.3) pg/ml than those at the tenth day 1.9 
± (1.1) pg/ml with p-value <0.001*. Similarly, the ul-
cer swabs showed statistically significantly higher mean 
VEGF levels at the second day of ulcer activity 1220.7 ± 
(294.6) pg/ml than those at the tenth day 788.5 ± (152.0) 
pg/ml with p-value <0.001* (Table 1).
Comparison of Endocan and VEGF level between study 
and control sides
At the second day of ulcer activity, the ulcer swabs 
showed statistically significantly higher mean endocan 
and VEGF levels 8.2 ± (5.3) and 1220.7 ± (294.6) pg/
ml respectively than those of the healthy mucosa 1.1 ± 
(0.5) and 518.6 ± (61.7) pg/ml respectively with P-value 
< 0.001 and < 0.001, respectively. Similarly, during hea-
         Variable At the second day At the tenth day P-value
Pain
Mean (SD) 3.6 (0.9) 1.0 (0.7) <0.001*
Median (Range) 3.5 (2.0 – 5.0) 1.0 (0.0 – 2.0)
Ulcer size (mm2)
Mean (SD) 35.1 (9.8) 11.6 (5.8) <0.001*
Median (Range) 35.5 (19.6 – 50.3) 11.8 (3.1 – 19.6)
Endocan (pg/ml)
Mean (SD) 8.2 (5.3) 1.9 (1.1) <0.001*
Median (Range) 6.4 (2.4 – 20.5) 2.0 (0.4 – 4.2)
VEGF (pg/ml)
Mean (SD) 1220.7 (294.6) 788.5 (152.0) <0.001*
Median (Range) 1137.5 (826.0 – 1698.0) 764.0 (537.0 – 1025.0)
Table 1: Descriptive statistics and results of Wilcoxon signed rank test for the changes in different variables.
*: Significant at P ≤ 0.05.
Time Variable Ulcer side Healthy side P-value
 At the second day Endocan (pg/ml)
Mean ± (SD) 8.2± (5.3) 1.1± (0.5) <0.001*
VEGF (pg/ml)
Mean ± (SD) 1220.7 ± (294.6) 518.6 ± (61.7) <0.001*
At the tenth day Endocan (pg/ml)
Mean (SD) 1.9± (1.1) 1.1 ± (0.5) 0.009*
VEGF (pg/ml)
Mean ± (SD) 788.5±  (152.0) 518.6± (61.7) <0.001*
Table 2: Descriptive statistics and results of Wilcoxon signed-rank test for comparison between study and control sides.
*: Significant at P ≤ 0.05.
ling at the tenth day; the ulcer swabs showed statistica-
lly significantly higher mean endocan and VEGF levels 
1.9 ± (1.1) and 788.5 ± (152.0) pg/ml respectively than 
those of the healthy mucosal site 1.1 ± (0.5) and 518.6± 
(61.7) pg/ml respectively P-value = 0.009 and < 0.001, 
respectively (Table 2).
Correlation between different variables in the study side
At the second day, there was a statistically significant po-
sitive (direct) correlation between endocan and pain score; 
i.e. an elevation in endocan is associated with an elevation 
in pain score and vice versa (Fig. 1). There was also a statis-
tically significant positive (direct) correlation between en-
docan and VEGF; i.e. an elevation in endocan is associated 
with an elevation in VEGF and vice versa (Fig. 2).
No statistically significant correlation was found be-
tween (endocan and ulcer size), (VEGF and pain score) 
as well as (VEGF and ulcer size).
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Fig. 1: Scatter diagram representing direct correlation between endocan and pain scores at second day.
Fig. 2: Scatter diagram representing direct correlation between Endocan and VEGF at second day.
At the tenth day, there was no statistically significant co-
rrelation between any of the different variables (Table 
3).
Discussion
Although the exact aetiology of RAU is unknown, seve-
ral investigations have suggested immunodysregulation 
in this patients (2,20,21). Many studies also emphasized 
the role of the autoimmunity in the disease development. 
Disturbance of acquired as well as innate immune res-
ponse may occur in patients with RAU demonstrated as 
elevated levels of the complement proteins, neutrophils 
hyper-reactivity, elevated amount of B lymphocytes and 
NK cells, in addition to disruption of the CD4/CD8 ratio 
and elevated amount of T cell receptor (TCR) and CD25 
cells in peripheral circulation (11,22). 
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Time Variables Correlation coefficient (r) P-value
At the second day Endocan and pain score 0.693 0.001*
Endocan and ulcer size -0.325 0.163
Endocan and VEGF 0.666 0.001*
VEGF and pain score 0.350 0.130
VEGF and ulcer size -0.112 0.639
At the   tenth day Endocan and pain score 0.320 0.170
Endocan and ulcer size -0.321 0.167
Endocan and VEGF 0.176 0.457
VEGF and pain score 0.172 0.469
VEGF and ulcer size -0.356 0.124
Table 3: Results of Spearman’s correlation coefficient for the correlation between different variables.
*: Significant at P ≤ 0.05.
Endothelial cells are in charge of leukocytes attraction 
which are recruited early in inflammatory response (23). 
The Th1 immunologic response is suggested by many 
authors to have a crucial role in the progression of RAU 
(20,21,24). This was supported by Lewkowicz et al. (25) 
who reported a significant increase of Th1 cytokines in 
RAU patients in contrast to healthy subjects.
Vascular endothelial growth factor (VEGF) is produced 
by platelets and plays an imperative role in proteolytic 
enzyme secretion, proliferation of endothelial cell, and 
cell emigration via chemotaxis; in addition to its angio-
genesis stimulating function (26).
Endocan, a soluble proteoglycan secreted by vascular 
endothelial cells and it is primarily regulated by various 
inflammatory cytokines as IL-1 and TNF-a. In addition 
to VEGF-A which is also implicated in the action of en-
docan. Moreover, some experimental studies proposed 
endocan as a strategic regulator of inflammatory disor-
ders, cellular adhesion, and cancer development. The-
refore, it is considered an endothelial immunoinflam-
matory marker (17,27).
To the best of our knowledge, the present research is the 
first to evaluate the role of endocan in the pathogenesis 
of recurrent aphthous ulcer.
The present research aimed to evaluate the pain severity, 
ulcer size, and cytological profile of both endocan and 
VEGF in RAU in the active phase at the second day and 
in the healing phase at the tenth day.  Pain score as well 
as ulcer size were found to significantly decrease from 
the second day of ulcer development to the tenth day. 
Both findings are consistent with the self-limiting na-
ture of RAU aphthous in which healing usually occurs 
within 10-14 days (2). Accordingly at day ten ulcers had 
already entered the healing phase with reduction in ulcer 
size and consequently pain score being a symptom of 
active destruction .
Since no previous studies evaluated endocan levels in 
oral exfoliative cytology specimens in aphthous ulcers, 
it is hard to compare our results directly with other re-
searches. However, several studies reported a significant 
increase in serum level of endocan in other inflammatory 
disorders as septic shock (28), psoriasis vulgaris (29), 
cardiovascular events (17) and chronic kidney disease 
(30). Other studies reported that endocan level can be 
elevated in malignancies, however the regulation of its 
secretion and synthesis carried out via proinflammatory 
cytokines, as well as angiogenic factors like VEGF 
(31,32).
Moreover, endocan has been strongly associated with 
Behçet Disease which is an inflammatory condition 
characterized by more than 95% occurrence of oral aph-
thous like ulcers (33).
Findings of the present study showed that mean levels 
of endocan was statistically significantly higher in oral 
RAU lesions than control side either at second day or at 
day ten. Moreover, the ulcer swabs showed statistically 
significantly higher mean endocan levels at the second 
day of ulcer activity than those at the tenth day during 
the healing phase indicating the strong association of en-
docan with acute destructive phase of the disease. 
Balta et al. (27) reported that endocan levels in serum 
of Behçet Disease patients were significantly higher 
than control and discovered that serum endocan levels 
directly correlated with erythrocyte sedimentation rate, 
C-reactive protein, and with disease activity. Moreover, 
endocan levels were greater in patients suffering from 
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systemic manifestations, and they concluded that endo-
can may impact both endothelial function and the in-
flammatory process through the pathogenesis of Behçet 
Disease and attributed the elevated endocan levels found 
in those patients to the LFA-1/ICAM- 1 pathway inhibi-
tion; and stimulation of endocan expression by the rai-
sed VEGF plasma levels in Behçet Disease patients (34).
Additionally our results revealed a statistically signifi-
cant positive (direct) correlation between endocan levels 
and pain score, where an increase in endocan level was 
associated with an elevation in pain score and vice versa 
indicating that endocan is more strongly associated with 
disease severity and active destructive phase of minor 
aphthous ulcers.  
The higher level of endocan can be explained by the fact 
that many of cytokines and growth factors regulate its 
expression (17). Where it was found that TNF-α and IL- 
1β and VEGF had been shown to prompt endocan ex-
pression (35). Since it has been reported that such cyto-
kines and growth factors are directly involved and may 
be overexpressed during the destructive process of oral 
aphthous ulcer (2,10). Consequently this could explain 
the elevated endocan levels encountered in RAU lesions 
in the present study.
Another explanation is that endocan may be involved 
in regulating leukocyte extravasation at sites of inflam-
mation, due to the importance of the ICAM-1/LFA-1 
interactions for secure adhesion of monocytes and lym-
phocytes. In addition, endocan could modify the LFA-1/
ICAM-1 co-stimulatory pathway on T cells and could 
modulate the balance of Th1/Th2 in the immune res-
ponse (34). Such balance is disturbed favoring Th1 type 
immunologic response which is proposed by many au-
thors to play the fundamental role in RAU development 
(21,22,25) reflecting a conceivable connection of endo-
can to the pathogenesis of RAU.
The present study also investigated the levels of VEGF in 
oral RAU due to its relation to endocan as endocan synthe-
sis is enhanced during inflammatory processes, and VEGF 
is found to promote inflammatory reactions by mobilizing 
leukocytes (25). Furthermore, VEGF itself was reported to 
upregulate endocan expression (18). This link was endor-
sed by the results of the present study where a statistically 
significant positive (direct) correlation between endocan 
and VEGF was found during the dynamic phase of the di-
sease as an increase in endocan level was associated with 
an increase in VEGF level and vice versa.
Morover, VEGF is considered as a potent angiogenic 
factor in the pathogenesis of vasculitis of aphthous ul-
cers which are characterized by great angiogenic action 
and a loss of the epithelial integrity in the oral mucosa 
(36). Hence, anti-angiogenic treatments as thalidomide 
have been proposed to endorse healing of oral ulcers and 
to control the frequency of recurrences (14). Moreover, 
VEGF induces vascular thrombosis and inflammation 
via stimulating endothelial cells causing the release of 
vasoactive substances (37).
While investigating VEGF levels in the present study 
mean levels of VEGF was statistically significantly hi-
gher in diseased side than control side either at second 
day or at day ten. Moreover, the ulcer swabs showed 
statistically significantly higher mean VEGF levels at 
the second day of ulcer activity than those at the tenth 
day during the healing phase. This evident association 
linking VEGF to the ulcerative process identified in our 
study is consistent with former studies associating the 
levels of VEGF with oral aphthous ulceration and with 
proof from other ulcer-related disorders as Behçet Di-
sease where clinical proof advocates that VEGF could 
be directly involved in oral ulcers formation in Behçet 
Disease (11,14,37,38). Finally, an association between 
the genetic pathway of VEGF and the occurrence of oral 
ulcers have been recognized and validated the in Syste-
mic Lupus Erythematosus (39).
Furthermore, topical steroidal and non-steroidal thera-
pies that have been utilized effectively for the manage-
ment of RAU are found to considerably affect the VEGF 
pathway genes expression designating that the VEGF 
pathway might be a significant mediator of the benefits 
of immunotherapeutic agents for oral ulcers. 
Conclusions
The results of the present investigation revealed a strong 
association of Endocan and VEGF levels with the des-
tructive phase of RAU with Endocan levels being more 
directly correlated to pain scores. Furthermore a signi-
ficant positive correlation between Endocan levels and 
VEGF levels was evident validating the interrelation be-
tween these two markers during the ulcerative process. 
Therefore, our findings suggest that the Endocan and 
VEGF interconnection along with their association with 
the phase of active destruction might offer new insights 
for a novel anti-inflammatory strategy of oral RAU that 
might allow more specific remedy while avoiding the 
detrimental side effects of existing therapies.
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